Study of Docosahexaenoic Acid (DHA) Supplementation in Patients With X-Linked Retinitis Pigmentosa
Status:
Completed
Trial end date:
2002-06-01
Target enrollment:
Participant gender:
Summary
OBJECTIVES:
I. Evaluate the potential of nutritional docosahexaenoic acid (DHA) supplementation to
normalize the level of DHA in red blood cells, and to retard the progression of visual
function loss in patients with early stage X-linked retinitis pigmentosa.